These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Development of a novel Indium-111 radiolabeled mogamulizumab targeting CCR4 for imaging adult T-cell leukemia/lymphoma in vivo. Shimizu Y; Koyasu S; Suzukida M; Izumi K; Kidera E; Shindo T; Saga T; Ono M; Takaori-Kondo A; Nakamoto Y Ann Nucl Med; 2022 Mar; 36(3):319-326. PubMed ID: 35034259 [TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T-cell leukemia/lymphoma: A retrospective analysis. Satake A; Konishi A; Azuma Y; Tsubokura Y; Yoshimura H; Hotta M; Nakanishi T; Fujita S; Nakaya A; Ito T; Ishii K; Nomura S Eur J Haematol; 2020 Dec; 105(6):704-711. PubMed ID: 32564395 [TBL] [Abstract][Full Text] [Related]
14. Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas. Tobinai K; Takahashi T; Akinaga S Curr Hematol Malig Rep; 2012 Sep; 7(3):235-40. PubMed ID: 22538464 [TBL] [Abstract][Full Text] [Related]
15. Clinical Impact of a Humanized CCR4 Antibody (Mogamulizumab) in 14 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated at a Single Institution During a Three-year Period (2012-2014). Kawano N; Kuriyama T; Sonoda KH; Yoshida S; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I Intern Med; 2016; 55(11):1439-45. PubMed ID: 27250049 [TBL] [Abstract][Full Text] [Related]
16. CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment. Sakamoto Y; Ishida T; Masaki A; Murase T; Yonekura K; Tashiro Y; Tokunaga M; Utsunomiya A; Ito A; Kusumoto S; Iida S; Ueda R; Inagaki H Blood; 2018 Aug; 132(7):758-761. PubMed ID: 29930010 [No Abstract] [Full Text] [Related]
17. Development of Engineered T Cells Expressing a Chimeric CD16-CD3ΞΆ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia. Tanaka H; Fujiwara H; Ochi F; Tanimoto K; Casey N; Okamoto S; Mineno J; Kuzushima K; Shiku H; Sugiyama T; Barrett AJ; Yasukawa M Clin Cancer Res; 2016 Sep; 22(17):4405-16. PubMed ID: 27091408 [TBL] [Abstract][Full Text] [Related]
18. Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma. Sakamoto Y; Ishida T; Masaki A; Murase T; Takeshita M; Muto R; Iwasaki H; Ito A; Kusumoto S; Nakano N; Tokunaga M; Yonekura K; Tashiro Y; Iida S; Utsunomiya A; Ueda R; Inagaki H Br J Haematol; 2021 Nov; 195(4):571-584. PubMed ID: 34405395 [TBL] [Abstract][Full Text] [Related]
19. [Adult T cell leukemia-lymphoma with allo-HSCT after treatment for pulmonary involvement with Mogamulizumab]. Kawashima I; Sueki Y; Yamamoto T; Nozaki Y; Nakajima K; Mitsumori T; Kirito K Rinsho Ketsueki; 2015 Feb; 56(2):210-5. PubMed ID: 25765802 [TBL] [Abstract][Full Text] [Related]
20. Galectin-9 as a Predictive Marker for the Onset of Immune-Related Adverse Effects Associated with Anti-CCR4 MoAb Therapy in Patients with Adult T Cell Leukemia. Mohammed TO; Chagan-Yasutan H; Ashino Y; Nakayama W; Takahashi Y; Shimomura T; Fujimoto T; Watanabe Y; Niki T; Suzushima H; Hattori T Tohoku J Exp Med; 2017 Mar; 241(3):201-208. PubMed ID: 28321034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]